(UroToday.com) At the 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium during the session on practical applications of novel imaging and genomic approaches in the management of clinically localized prostate cancer, Dr. Anuradha Gopalan discussed redefining high-risk prostate cancer beyond clinical parameters. Dr. Gopalan notes that in the latest National Comprehensive Cancer Network (NCCN) guidelines for prostate cancer, the percentage of positive cores in intermediate-risk prostate cancer depicts whether patients are favorable intermediate (<50% biopsy cores positive) or unfavorable intermediate-risk (>50% biopsy cores positive) denoting the importance of core positivity percentage.